Agranulocytosis and Hemolytic Anemia in Patients With Renal Cell Cancer Treated With Interleukin-12

Journal of Immunotherapy

Volumn 24, Issue 1, 2001, Pages 91-98

  Gollob, Jared A ^a   Veenstra, Korina G ^a   Mier, James W ^a   Atkins, Michael B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Agranulocytosis; Cancer; Hemolysis; Interleukin 12

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RECOMBINANT INTERLEUKIN 12;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL TRIAL; FEMALE; HEMOLYTIC ANEMIA; HUMAN; KIDNEY CARCINOMA; LARGE GRANULAR LYMPHOCYTE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SPLENOMEGALY;

AGED; ANEMIA, HEMOLYTIC; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-12; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 0035135745     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200101000-00011     Document Type: Article

References (32)

1. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84:4008-27.
2. Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two β type cytokine receptor subunits. Proc Natl Acad Sci USA 1997; 93:14002-7.
3. Grohmann U, Belladonna ML, Bianchi R, et al. IL-12 acts directly on DC to promote nuclear localization of NF-κB and primes DC for IL-12 production. Immunity 1998; 9:315-23.
4. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-1230.
5. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 1994; 153:1607-1706.
6. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87:581-6.
7. Murray H, Hariprashad J. Interleukin 12 is effective treatment of an established intracellular infection: experimental visceral leishmaniasis. J Exp Med 1995; 181:387-91.
8. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280:1432-5.
9. Trinchieri G. Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 1993; 14:335-8.
10. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995; 181:817-21.
11. McIntyre KW, Shuster DJ, Gillooly KM, et al. Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur J Immunol 1996; 26:2933-8.
12. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182:1281-90.
13. Jacobson SEW, Veiby OP, Smeland EB. Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells. J Exp Med 1993; 178:413-18.
14. Bellone G, Trinchieri G. Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 1994; 153:930-7.
15. Jackson JD, Yan Y, Brunda MJ, Kelsey LS, Talmadge JE. Interleukin-12 enhances peripheral hematopoiesis in vivo. Blood 1995; 85:2371-6.
16. Eng VM, Car BD, Schnyder B, et al. The stimulatory effects of interleukin (il)-12 on hematopoiesis are antagonized by il-12-induced interferon γ in vivo. J Exp Med 1995; 181:1893-8.
17. Gollob JA, Atkins MB. Clinical trials of interleukin-12 in oncology. Curr Opin Oncol Endoc Metab Invest Drugs 1999; 1:260-71.
18. Atkins M, Robertson M, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3:409-17.
19. Bajetta A, Vecchio MD, Mortarini R, et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 1998; 4:75-85.
20. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice weekly intravenous interleukin-12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin Cancer Res 2000; 6:1678-92.
21. Gollob JA, Kawasaki H, Ritz J. Interferon-γ and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. Eur J Immunol 1997; 27:647-52.
22. Gollob JA, Li J, Reinherz EL, Ritz J. CD2 regulates responsiveness of activated T cells to interleukin 12. J Exp Med 1995; 182:721-31.
23. Thompson JA, Lee DJ, Lindgren CG, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6:669-78.
24. Quesada JR. Biologic therapy with interferon-γ. In: DeVita Jr, VT Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia: JB Lippincott, 1995:435-42.
25. Creaven PJ, Brenner DE, Cowers JW, et al. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 1989; 23:186-91.
26. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335:1350-6.
27. Bemiller LS, Roberts DH, Starko KM, Curnutte JT. Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Mol Dis 1995; 21:239-47.
28. Binder D, van den Brek MF, Kagi D, et al. Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+ T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med 1998; 187:1903-20.
29. Carpenter CB. The major histocompatability gene complex. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, eds. Harrison's Principles of Internal Medicine. New York: McGraw Hill, 1987, 337-42.
30. Burmester GR, Daser A, Kamradt T, et al. Immunology of reactive arthritides. Annu Rev Immunol 1995; 13:229-50.
31. Nepom BS. The role of the major histocompatibility complex in autoimmunity. Clin Immunol Immunopathol 1993; 67:S50-5.
32. Fossati-Jimack L, Reininger L, Chicheportiche Y, et al. High pathogenic potential of low-affinity auotoantibodies in experimental autoimmune hemolytic anemia. J Exp Med 1999; 190:1689-96.